<DOC>
	<DOCNO>NCT02097680</DOCNO>
	<brief_summary>It seem plausible increased aromatase activity obese men , result large fat mass , responsible decreased level testosterone . Therefore aromatase inhibition increase testosterone level , may affect hepatic cardiac function . In intervention study two group hypogonadal obese men compare . Group A treat Letrozole 2.5 mg ( aromatase inhibitor ) every two day four month ; group normal testosterone low oestrogen concentration . Group B treat placebo every two day four month ; group retain low testosterone - high oestrogenic concentration . The primary objective study evaluate effect change sex steroid obese men hepatic cardiac function .</brief_summary>
	<brief_title>Influence Aromatase Inhibition Hepatic- Cardiac Function Severe Obese Men</brief_title>
	<detailed_description />
	<mesh_term>Letrozole</mesh_term>
	<criteria>Obese male subject Planned gastric bypass ( BMI &gt; 30 kg/mÂ² ) low testosterone level age 20 65 Primary hypogonadism secondary hypogonadism due genetic cause ( Kallman syndrome etc . ) , tumour , infiltrative disease , infection , pituitary apoplexy , trauma , critical illness , chronic systemic illness intentional . Treatment corticoid , opiate ( daily basis ) , androgen estrogen analog CYP2A6 substrate ( Dexmedetomidine , Ifosfamide , Methoxsalen , Miconazole , Tranylcypromine ) . Impaired renal function define serumcreatine &gt; 1.5 mg/dL Clinically significant active cardiovascular disease include history myocardial infarction within past 6 month and/or heart failure ( NYHA class III IV ) discretion investigator Cancer clinically significant disease disorder , investigator 's opinion could interfere result trial Palpable prostate nodule induration , Prostatespecific antigen ( PSA ) &gt; 3 ng/mL , prostatism , untreated sleep apnea syndrome , erythrocytosis ( hematocrit &gt; 50 % ) hyperviscosity . ( cfr . Endocrine Society Clinical Practice Guideline Bhasin S et al . ) Known suspect abuse alcohol narcotic</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>disturb glucose metabolism</keyword>
	<keyword>without disturb glucose metabolism</keyword>
</DOC>